Greten, Tim F.

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 13,097

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 6,645

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications

Immune cells in cancerImmunotherapy and Immune Responses

Cited by 2,751

IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer

Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell

NF-κB Signaling PathwaysSignaling Pathways in Disease

Cited by 2,433

Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells

Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science

Gut microbiota and healthCholangiocarcinoma and Gallbladder Cancer Studies

Cited by 1,508

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisRenal cell carcinoma treatment

Cited by 1,044

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

Hoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology

Immune cells in cancerImmunotherapy and Immune Responses

Cited by 793

NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis

Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., Stroncek, D. F., Terabe, M., Kapoor, V., ElGindi, M., et al. (2016) · Nature

Liver Disease Diagnosis and TreatmentCancer, Lipids, and Metabolism

Cited by 766

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes –Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesPancreatic and Hepatic Oncology Research

Cited by 611

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression

Eggert, T., Wolter, K., Ji, J., Ma, C., Yevsa, T., Klotz, S., Medina-Echeverz, J., Longerich, T., Forgues, M., Reisinger, F., et al. (2016) · Cancer Cell

Immune cells in cancerTelomeres, Telomerase, and Senescence

Cited by 609

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology

Hepatocellular Carcinoma Treatment and PrognosisStatistical Methods in Clinical Trials

Cited by 413

Myeloid derived suppressor cells in human diseases

Greten, T. F., Manns, M. P., & Korangy, F. (2011) · International Immunopharmacology

Immune cells in cancerImmunotherapy and Immune Responses

Cited by 398

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and Treatment

Cited by 354

Biomarkers for immunotherapy of hepatocellular carcinoma

Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 227

CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma

Diggs, L. P., Ruf, B., Ma, C., Heinrich, B., Cui, L., Zhang, Q., McVey, J. C., Wabitsch, S., Heinrich, S., Rosato, U., et al. (2021) · Journal of Hepatology

Cholangiocarcinoma and Gallbladder Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 151

SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases

Trehan, R., Huang, P., Zhu, X. B., Wang, X., Soliman, M., Strepay, D., Nur, A., Kedei, N., Arhin, M., Ghabra, S., et al. (2025) · Nature Communications

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 74

Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients

Chen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 67

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

Deming, D. A., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Eickhoff, J. C., Kolesar, J. M., Fioravanti, S., Greten, T. F., Compton, K., et al. (2016) · Investigational New Drugs

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 52

Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab

Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., et al. (2025) · Gut

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 24